Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies

References

• MahieuMYountSRamsey-GoldmanRPatient-reported outcomes in systemic lupus erythematosusRheum Dis Clin North Am201642225326327133488
   PubMed Web of Science ®Google Scholar
• KwanAStrandVToumaZThe role of patient reported outcomes in systemic lupus erythematosusCurr Treat Options Neurol201734308321
   Google Scholar
• StrandVGladmanDIsenbergDPetriMSmolenJTugwellPOutcome measures to be used in clinical trials in systemic lupus erythematosusJ Rheumatol19992624904979972993
   PubMed Web of Science ®Google Scholar
• Guidance for Industry: Systemic Lupus Erythematosus – Developing Medical Products for Treatment2010 Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdfAccessed December 12, 2018
   Google Scholar
• MoscaMCostenbaderKHJohnsonSRHow do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteriaArthritis Rheumatol Epub2018723
   Google Scholar
• ParksCGde Souza Espindola SantosABarbhaiyaMCostenbaderKHUnderstanding the role of environmental factors in the development of systemic lupus erythematosusBest Pract Res Clin Rheumatol201731330632029224673
   PubMed Web of Science ®Google Scholar
• KaulAGordonCCrowMKSystemic lupus erythematosusNat Rev Dis Primers201621603927306639
   PubMed Web of Science ®Google Scholar
• Wahren-HerleniusMDörnerTImmunopathogenic mechanisms of systemic autoimmune diseaseLancet2013382989481983123993191
   PubMed Web of Science ®Google Scholar
• BarturenGAlarcon-RiquelmeMESLE redefined on the basis of molecular pathwaysBest Pract Res Clin Rheumatol201731329130529224672
   PubMed Web of Science ®Google Scholar
• DörnerTLipskyPEBeyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLENat Rev Rheumatol2016121164565727733759
   PubMed Web of Science ®Google Scholar
• ToumaZGladmanDDCurrent and future therapies for SLE: obstacles and recommendations for the development of novel treatmentsLupus Sci Med201741e00023929344386
   PubMed Web of Science ®Google Scholar
• Al RayesHToumaZProfile of epratuzumab and its potential in the treatment of systemic lupus erythematosusDrug Des Devel Ther2014823032310
   PubMed Web of Science ®Google Scholar
• BlairHADugganSTBelimumab: a review in systemic lupus erythematosusDrugs201878335536629396833
   PubMed Web of Science ®Google Scholar
• CrowMKNiewoldTBKirouKACytokines and interferons in lupusWallaceDJHahnBHDubois’ Lupus Erythematosus and Related Syndromes8th edPhiladelphia, PAElsevier/Saunders20136275
   Google Scholar
• StohlWMetyasSTanSMB lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsArthritis Rheum200348123475348614673998
   PubMed Web of Science ®Google Scholar
• StohlWInhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)Expert Rev Clin Immunol201713662363328164726
   PubMed Web of Science ®Google Scholar
• JacobiAMHuangWWangTEffect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging studyArthritis Rheum201062120121020039404
   PubMed Web of Science ®Google Scholar
• GSK receives European marketing authorisation for self-injectable formulation of Benlysta for the treatment of systemic lupus erythematosus Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-for-self-injectable-formulation-of-benlysta-for-the-treatment-of-systemic-lupus-erythematosus/Accessed December 20, 2018
   Google Scholar
• ElaloufOKeelingSOToumaZSubcutaneous belimumab in the treatment of systemic lupus erythematosusImmunotherapy201810131163117330105936
   PubMed Web of Science ®Google Scholar
• NavarraSVGuzmánRMGallacherAEBLISS-52 Study GroupEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialLancet2011377976772173121296403
   PubMed Web of Science ®Google Scholar
• FurieRPetriMZamaniOBLISS-76 Study GroupA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis Rheum201163123918393022127708
   PubMed Web of Science ®Google Scholar
• ZhangFBaeSCBassDA pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South KoreaAnn Rheum Dis201877335536329295825
   PubMed Web of Science ®Google Scholar
• StohlWSchwartingAOkadaMEfficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled studyArthrits Rheumatol201769510161027
   PubMed Web of Science ®Google Scholar
• WangCMayoNEFortinPRThe relationship between health related quality of life and disease activity and damage in systemic lupus erythematosusJ Rheumatol200128352553211296953
   PubMed Web of Science ®Google Scholar
• ToumaZSayaniAPineauCABelimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the observe Canada StudyRheumatol Int201737686587328280970
   PubMed Web of Science ®Google Scholar
• CollinsCEDall’EraMKanHResponse to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the observe study in the USALupus Sci Med201631e00011826835146
   PubMed Web of Science ®Google Scholar
• KimSSKirouKAErkanDBelimumab in systemic lupus erythematosus: an update for cliniciansTherap Adv Chron Dis2012311123
   Google Scholar
• van VollenhovenRFPetriMACerveraRBelimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnn Rheum Dis20127181343134922337213
   PubMed Web of Science ®Google Scholar
• GinzlerEMWallaceDJMerrillJTLBSL02/99 Study GroupDisease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusJ Rheumatol201441230030924187095
   PubMed Web of Science ®Google Scholar
• StrandVLevyRACerveraRBLISS-52 and -76 Study GroupsImprovements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trialsAnn Rheum Dis201473583884423524886
   PubMed Web of Science ®Google Scholar
• FurieRPetriMAStrandVGladmanDDZhongZJFreimuthWWBLISS-52 and BLISS-76 Study GroupsClinical, laboratory and health-related quality of life correlates of Systemic lupus erythematosus responder index response: a post hoc analysis of the phase 3 belimumab trialsLupus Sci Med201411e00003125396065
   PubMedGoogle Scholar
• HollowayLHumphreyLHeronLPatient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performanceHealth Qual Life Outcomes20141211625048687
   PubMed Web of Science ®Google Scholar
• WareJESherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care19923064734831593914
   PubMed Web of Science ®Google Scholar
• KianiANStrandVFangHJaranillaJPetriMPredictors of self-reported health-related quality of life in systemic lupus erythematosusRheumatology (Oxford)20135291651165723681396
   PubMed Web of Science ®Google Scholar
• MokCCHoLYCheungMYYuKLToCHEffect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective studyScand J Rheumatol200938212112718991189
   PubMed Web of Science ®Google Scholar
• UrowitzMGladmanDDIbanezDChanges in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosusArthritis Care Res (Hoboken)20146691374137924497416
   PubMed Web of Science ®Google Scholar
• RaiSKYazdanyJFortinPRAvina-ZubietaJAApproaches for estimating minimal clinically important differences in systemic lupus erythematosusArthritis Res Ther20151714326036334
   PubMed Web of Science ®Google Scholar
• AnnapureddyNDevilliersHJollyMPatient-reported outcomes in lupus clinical trials with biologicsLupus201625101111112127497256
   PubMed Web of Science ®Google Scholar
• ThumbooJFengPHBoeyMLSohCHThioSFongKYValidation of the Chinese SF-36 for quality of life assessment in patients with systemic lupus erythematosusLupus20009970871211199927
   PubMed Web of Science ®Google Scholar
• ThumbooJFongKYNgTPLeongKHFengPHThioSTBoeyMLValidation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in SingaporeJ Rheumatol1999261971029918248
   PubMed Web of Science ®Google Scholar
• BabaSKatsumataYOkamotoYKawaguchiYHanaokaMKawasumiHYamanakaHReliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective studyLupus201827340741628795653
   PubMed Web of Science ®Google Scholar
• NantesSGStrandVSuJToumaZComparison of the sensitivity to change of the 36-item short form health survey and the lupus quality of life measure using various definitions of minimum clinically important differences in patients with active systemic lupus erythematosusArthritis Care Res (Hoboken)201870112513328320078
   PubMed Web of Science ®Google Scholar
• ToumaZGladmanDDIbañezDUrowitzMBIs there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?J Rheumatol20113891898190521724700
   PubMed Web of Science ®Google Scholar
• Yilmaz-OnerSOnerCDogukanFMHealth-related quality of life assessed by LupusQoL questionnaire and SF-36 in Turkish patients with systemic lupus erythematosusClin Rheumatol201635361762225846834
   PubMed Web of Science ®Google Scholar
• McElhoneKAbbottJSuttonCSensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosusArthritis Care Res (Hoboken)201668101505151326816223
   PubMed Web of Science ®Google Scholar
• Garcia-CarrascoMMendoza-PintoCCardielMHHealth related quality of life in Mexican women with systemic lupus erythematosus: a descriptive study using SF-36 and LupusQoL(C)Lupus201221111219122422875651
   PubMed Web of Science ®Google Scholar
• DevilliersHAmouraZBesancenotJFResponsiveness of the 36-item short form health survey and the lupus quality of life questionnaire in SLERheumatology (Oxford)201554594094925361539
   PubMed Web of Science ®Google Scholar
• EngelLBeatonDEToumaZMinimal clinically important difference: a review of outcome measure score interpretationRheum Dis Clin North Am201844217718829622290
   PubMed Web of Science ®Google Scholar
• StrandVCrawfordBImprovement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodiesExpert Rev Pharmacoecon Outcomes Res20055331732619807601
   PubMedGoogle Scholar
• StrandVAranowCCardielMHLJP 394 Investigator ConsortiumImprovement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placeboLupus200312967768614514130
   PubMed Web of Science ®Google Scholar
• GoligherECPouchotJBrantRMinimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosusJ Rheumatol200835463564218322987
   PubMed Web of Science ®Google Scholar
• CellaDManual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement SystemEvanston, ILCenter on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University1997
   Google Scholar
• YellenSBCellaDFWebsterKBlendowskiCKaplanEMeasuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJ Pain Symptom Manage199713263749095563
   PubMed Web of Science ®Google Scholar
• KosinskiMGajriaKFernandesAWCellaDQualitative validation of the FACIT-fatigue scale in systemic lupus erythematosusLupus201322542243023423250
   PubMed Web of Science ®Google Scholar
• LaiJSBeaumontJLOgaleSBrunettaPCellaDValidation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trialJ Rheumatol201138467267921239746
   PubMed Web of Science ®Google Scholar
• StrandVChuADGeneric versus disease-specific measures of health-related quality of life in systemic lupus erythematosusJ Rheumatol20113891821182321885504
   PubMed Web of Science ®Google Scholar
• ThumbooJStrandVHealth-related quality of life in patients with systemic lupus erythematosus: an updateAnn Acad Med Singapore200736211512217364078
   PubMed Web of Science ®Google Scholar
• IzadiZGandrupJKatzPPYazdanyJPatient-reported outcome measures for use in clinical trials of SLE: a reviewLupus Sci Med201851e00027930167315
   PubMed Web of Science ®Google Scholar
• ClowseMEWallaceDJFurieRAEMBODY Investigator GroupEfficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trialsArthritis Rheumatol201769236237527598855
   PubMed Web of Science ®Google Scholar
• FiechtnerJJMontroyTTreatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trialLupus201423990591224795067
   PubMed Web of Science ®Google Scholar